Zhang YL - Search Results

1

Downregulation of LINC00515 in high-grade serous ovarian cancer and its relationship with platinum resistance.

Ni MW, Zhou J, Zhang YL, Zhou GM, Zhang SJ, Feng JG, Xu Q, Zhou Y, Mou HZ, Zheng ZG. Ni MW, et al. Among authors: zhang sj, zhang yl. Biomark Med. 2019 May;13(7):535-543. doi: 10.2217/bmm-2018-0382. Epub 2019 May 29. Biomark Med. 2019. PMID: 31140829

2

[Inhibitory effect of a Chinese medicine Xiaoaiping combined with cisplatin on the proliferation, invasion and apoptosis in ovarian cancer HO-8910 PM cells in vitro and in vivo].

Zheng A, Li T, Chen Y, Fang J, Zhang Y, Feng J. Zheng A, et al. Zhonghua Zhong Liu Za Zhi. 2016 Jan;38(1):11-6. doi: 10.3760/cma.j.issn.0253-3766.2016.01.003. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 26796800 Chinese.

3

Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer.

Guo Y, Chen X, Tang X, Pan S, Zhu T, Zhang Y. Guo Y, et al. Curr Cancer Drug Targets. 2024 Jan 1. doi: 10.2174/0115680096271476231226174810. Online ahead of print. Curr Cancer Drug Targets. 2024. PMID: 38173064

4

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.

Shi T, Yin S, Zhu J, Zhang P, Liu J, Zhu Y, Wu S, Chen X, Wang X, Teng Y, Zhu T, Yu A, Zhang Y, Feng Y, Huang H, Bao W, Li Y, Jiang W, Zhang P, Li J, Ai Z, Zhang W, Jia H, Zhang Y, Jiang R, Zhang J, Gao W, Luan Y, Zang R. Shi T, et al. J Gynecol Oncol. 2020 May;31(3):e61. doi: 10.3802/jgo.2020.31.e61. J Gynecol Oncol. 2020. PMID: 32319233 Free PMC article. Clinical Trial.

5

The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.

Fang C, Zhang Y, Zhao L, Chen X, Xia L, Zhang P. Fang C, et al. BMC Cancer. 2020 Jul 13;20(1):654. doi: 10.1186/s12885-020-07144-1. BMC Cancer. 2020. PMID: 32660444 Free PMC article.

6

A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients.

Zhang Y, Shi X, Zhang J, Chen X, Zhang P, Liu A, Zhu T. Zhang Y, et al. Sci Rep. 2021 Jan 11;11(1):387. doi: 10.1038/s41598-020-79694-0. Sci Rep. 2021. PMID: 33432021 Free PMC article.

7

Prognostic and clinical significance of Solute Carrier Family 7 Member 1 in ovarian cancer.

Gong W, Chen Y, Zhang Y. Gong W, et al. Transl Cancer Res. 2021 Feb;10(2):602-612. doi: 10.21037/tcr-20-2744. Transl Cancer Res. 2021. PMID: 35116394 Free PMC article.

8

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma.

Zhao LQ, Gao W, Zhang P, Zhang YL, Fang CY, Shou HF. Zhao LQ, et al. Among authors: zhang p, zhang yl. World J Clin Cases. 2022 Apr 26;10(12):3739-3753. doi: 10.12998/wjcc.v10.i12.3739. World J Clin Cases. 2022. PMID: 35647161 Free PMC article.

9

Prognostic value of serum α-fetoprotein in ovarian yolk sac tumors: A systematic review and meta-analysis.

Guo YL, Zhang YL, Zhu JQ. Guo YL, et al. Among authors: zhang yl. Mol Clin Oncol. 2015 Jan;3(1):125-132. doi: 10.3892/mco.2014.417. Epub 2014 Sep 18. Mol Clin Oncol. 2015. PMID: 25469282 Free PMC article.

10

Xiaoaiping combined with cisplatin can inhibit proliferation and invasion and induce cell cycle arrest and apoptosis in human ovarian cancer cell lines.

Zheng AW, Chen YQ, Fang J, Zhang YL, Jia DD. Zheng AW, et al. Among authors: zhang yl. Biomed Pharmacother. 2017 May;89:1172-1177. doi: 10.1016/j.biopha.2017.03.012. Epub 2017 Mar 14. Biomed Pharmacother. 2017. PMID: 28320083

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,135 results

Search Page